We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00665613
First Posted: April 24, 2008
Last Update Posted: October 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Staten Island University Hospital
Information provided by (Responsible Party):
Mario Castellanos, North Shore Long Island Jewish Health System
  Purpose
The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.

Condition
Osteoporosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

Resource links provided by NLM:


Further study details as provided by Mario Castellanos, North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Bone Density [ Time Frame: 5 to 10 years ]
    bone density as measured by xray to assess bone strength nd risk of fracture


Enrollment: 300
Study Start Date: October 2004
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
patients on warfarintherapy in the SIUH coumadin center
Criteria

Inclusion Criteria:

  • Patients on warfarin that have had BMD within a year

Exclusion Criteria:

  • Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00665613


Locations
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Northwell Health
Staten Island University Hospital
  More Information

Responsible Party: Mario Castellanos, Clinical Director of Research for Dept. of Medicine, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00665613     History of Changes
Other Study ID Numbers: 04-054
First Submitted: April 22, 2008
First Posted: April 24, 2008
Last Update Posted: October 14, 2015
Last Verified: October 2015

Keywords provided by Mario Castellanos, North Shore Long Island Jewish Health System:
warfarin use

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Warfarin
Anticoagulants